LOX Lysyl-Oxidase

This gene found in gastric and bladder cancer is prognostic.  Its amplification allows the cell to deal with austere conditions in Metastatic conditions.  It seems to be amplifying under the impetus of HIF (Hypoxia induced factor). Its amplification appears more reactive than driving the resulting dowstream reaction.It can affect the structure of laminin and collagen through its formation of Aldehyde.
It can push proliferation by acting as a co-factor at nuclear level.
It can affect AKT (Protein Kinase B).
Recently, a study in Sarcoma using a Doxorubicin isoform was set in motion. Expression of LOX should be included in the analysis since Hypoxia was a component of the treatment.
LOX would not be a principal target in a treatment strategy since it addresses mostly metastasis, it either an adjunct treatment, or will have a role in Maintenance therapy.

IN METASTATIC DISEASE THAT IS ADVANCED, ONE OF THE GENE MENTIONED IS THE NME1/NM23A

This gene (Non Metastatic Cell 1) is expressed at 17q21.3 and produces protein NM23A.Contrary to its name, it is noted to be expressed in advanced Metastatic disease and as such could have prognosis indication.
Remember, there is that notion that if a Molecule found in Metastatic state is present in the early stage of a cancer, it is predictive of more advanced cancer, higher recurrence rate and higher mortality risk.